2. Flegal K.M., Kruszon-Moran D., Carroll M.D., Fryar C.D., Ogden C.L. Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–2291. Doi: 10.1001/jama.2016.6458.

3. Cattaneo A., Monasta L., Stamatakis E., Lioret S., Castetbon K., Frenken F., Manios Y., Moschonis G., Savva S., Zaborskis A., Rito A.I., Nanu M., Vignerova J., Caroli M., Ludvigsson J., Koch F.S., Serra-Majem L., Szponar L., van Lenthe F., Brug J. Overweight and obesity in infants and pre-school children in the European Union: a review of existing data. Obes. Rev. 2010;11(5):389–398. Doi: 10.1111/j.1467-789X.2009.00639.x.

4. Olaya B., Moneta M.V., Pez O., Bitfoi A., Carta M.G., Eke C., Goelitz D., Keyes K.M., Kuijpers R., Lesinskiene S., Mihova Z., Otten R., Fermanian C., Haro J.M., Kovess V. Country-level and individual correlates of overweight and obesity among primary school children: a cross-sectional study in seven European countries. BMC Public Health. 2015;15:475. Doi: 10.1186/s12889-015-1809-z.

5. Subramanian S.V., Perkins J.M., Özaltin E., Davey S.G. Weight of nations: a socioeconomic analysis of women in low- to middle-income countries. Am. J. Clin. Nutr. 2011;93(2):413–421. Doi: 10.3945/ajcn.110.004820.

6. Tsujimoto T., Sairenchi T., Iso H., Irie F., Yamagishi K., Watanabe H., Tanaka K., Muto T., Ota H. The dose-response relationship between body mass index and the risk of incident stage ≥3 chronic kidney disease in a general japanese population: the Ibaraki prefectural health study (IPHS). J. Epidemiol. 2014;24(6):444–451.

7. Elsayed E.F., Sarnak M.J., Tighiouart H., Griffith J.L., Kurth T., Salem D.N., Levey A.S., Weiner D.E. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am. J. Kidney Dis. 2008;52:29–38. Doi: 10.1053/j.ajkd.2008.02.363.

8. Pinto-Sietsma S.J., Navis G., Janssen W.M., de Zeeuw D., Gans R.O., de Jong P.E. A central body fat distribution is related to renal function impairment, even in lean subjects. Am. J. Kidney Dis. 2003;41(4):733–741.

9. Foster M.C., Hwang S.J., Larson M.G., Lichtman J.H., Parikh N.I., Vasan R.S., Levy D., Fox C.S. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am. J. Kidney Dis. 2008;52 (1):39–48. Doi: 10.1053/j.ajkd.2008.03.003.

10. Kramer H., Luke A., Bidani A., Cao G., Cooper R., McGee D. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am. J. Kidney Dis. 2005;46(4):587–594.

11. Chang A., Van H.L., Jacobs D.R. Jr., Liu K., Muntner P., Newsome B., Shoham D.A., Durazo-Arvizu R., Bibbins-Domingo K., Reis J., Kramer H. Lifestyle-related factors, obesity, and incident microalbuminuria: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am. J. Kidney Dis. 2013;62(2):267–275. Doi: 10.1053/j.ajkd.2013.02.363.

12. Ejerblad E., Fored C.M., Lindblad P., Fryzek J., McLaughlin J.K., Nyren O. Obesity and risk for chronic renal failure. J. Am. Soc. Nephrol. 2006;17(6):1695–1702.

13. Gelber R.P., Kurth T., Kausz A.T., Manson J.E., Buring J.E., Levey A.S., Gaziano J.M. Association between body mass index and CKD in apparently healthy men. Am. J. Kidney Dis. 2005;46(5):871–880.

14. Lu J.L., Molnar M.Z., Naseer A., Mikkelsen M.K., Kalantar-Zadeh K., Kovesdy C.P. Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol. 2015;3(9):704–714. Doi: 10.1016/S2213-8587(15)00128-X.

15. Munkhaugen J., Lydersen S., Wideroe T.E., Hallan S. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am. J. Kidney Dis. 2009;54(4):638–646. Doi: 10.1053/j.ajkd.2009.03.023.

16. Iseki K., Ikemiya Y., Kinjo K., Inoue T., Iseki C., Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65(5):1870–1876.

17. Vivante A., Golan E., Tzur D., Leiba A., Tirosh A., Skorecki K., Calderon-Margalit R. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch. Intern. Med. 2012;172(21):1644–1650.

18. Hsu C.Y., McCulloch C.E., Iribarren C., Darbinian J., Go A.S. Body mass index and risk for end-stage renal disease. Ann. Intern. Med. 2006;144(1):21–28.

19. Lu J.L., Kalantar-Zadeh K., Ma J.Z., Quarles L.D., Kovesdy C.P. Association of body mass index with outcomes in patients with CKD. J. Am. Soc. Nephrol. 2014;25(9):2088–2096. Doi: 10.1681/ASN.2013070754.

20. Thoenes M., Reil J.C., Khan B.V., Bramlage P., Volpe M., Kirch W., Bohm M. Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc. Health Risk Manag. 2009;5(4):577–585.

21. Kramer H., Gutierrez O.M., Judd S.E., Muntner P., Warnock D.G., Tanner R.M., Panwar B., Shoham D.A., McClellan W. Waist Circumference, Body Mass Index, and ESRD in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am. J. Kidney Dis. 2016;67(1):62–69. Doi: 10.1053/j.ajkd.2015.05.023.

22. Foster M.C., Hwang S.J., Massaro J.M., Hoffmann U., DeBoer I.H., Robins S.J., Vasan R.S., Fox C.S. Association of subcutaneous and visceral adiposity with albuminuria: the Framingham Heart Study. Obesity (Silver Spring). 2011;19(6):1284–1289. Doi: 10.1038/oby.2010.308.

23. Postorino M., Marino C., Tripepi G., Zoccali C. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J. Am. Coll. Cardiol. 2009;53(15):1265–1272. Doi: 10.1016/j.jacc.2008.12.040.

24. Kovesdy C.P., Czira M.E., Rudas A., Ujszaszi A., Rosivall L., Novak M., Kalantar-Zadeh K., Molnar M.Z., Mucsi I. Body mass index, waist circumference and mortality in kidney transplant recipients. Am. J. Transplant. 2010;10(12):2644–2651. Doi: 10.1111/j.1600-6143.2010.03330.x.

25. Scales C.D. Jr., Smith A.C., Hanley J.M., Saigal C.S. Prevalence of kidney stones in the United States. Eur. Urol. 2012;62(1):160–165. Doi: 10.1016/j.eururo.2012.03.052.

26. Curhan G.C., Willett W.C., Rimm E.B., Speizer F.E., Stampfer M.J. Body size and risk of kidney stones. J. Am. Soc. Nephrol. 1998;9(9):1645–1652.

27. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293(4):455–462.

28. Bhaskaran K., Douglas I., Forbes H., dos-Santos-Silva I., Leon D.A., Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384(9945):755–765. Doi: 10.1016/S0140-6736(14)60892-8.

29. Arnold M., Pandeya N., Byrnes G., Renehan A.G., Stevens G.A., Ezzati M., Ferlay J., Miranda J.J., Romieu I., Dikshit R., Forman D., Soerjomataram I. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36–46. Doi: 10.1016/S1470-2045(14)71123-4.

30. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–578. Doi: 10.1016/S0140-6736(08)60269-X.

31. Bluher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr. Opin. Lipidol. 2010;21(1):38–43. Doi: 10.1097/MOL.0b013e3283346ccc.

32. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 2009;76(2):145–148. Doi: 10.1038/ki.2009.137.

33. Wolf G., Ziyadeh F.N. Leptin and renal fibrosis. Contrib. Nephrol. 2006;151:175–183.

34. Ellington A.A., Malik A.R., Klee G.G., Turner S.T., Rule A.D., Mosley T.H. Jr., Kullo I.J. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension. 2007;50(4):708–714.

35. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., Capeau J., Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006;17(1):4–12.

36. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004;114(12):1752–1761.

37. Ruan X.Z., Varghese Z., Moorhead J.F. An update on the lipid nephrotoxicity hypothesis. Nat. Rev. Nephrol. 2009;5(12):713–721. Doi: 10.1038/nrneph.2009.184.

38. Ruster C., Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin. Nephrol. 2013;33(1):44–53. Doi: 10.1016/j.semnephrol.2012.12.002.

39. Oterdoom L.H., de Vries A.P., Gansevoort R.T., de Jong P.E., Gans R.O., Bakker S.J. Fasting insulin modifies the relation between age and renal function. Nephrol. Dial. Transplant. 2007;22(6):1587–1592.

40. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.

41. Kambham N., Markowitz G.S., Valeri A.M., Lin J., D’Agati V.D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498–1509.

42. de Vries A.P., Ruggenenti P., Ruan X.Z., Praga M., Cruzado J.M., Bajema I.M., D’Agati V.D., Lamb H.J., Pongrac B.D., Hojs R., Abbate M., Rodriquez R., Mogensen C.E., Porrini E. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417–426. Doi: 10.1016/S2213-8587(14)70065-8.

43. Foster M.C., Hwang S.J., Porter S.A., Massaro J.M., Hoffmann U., Fox C.S. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension. 2011;58(5):784–790. Doi: 10.1161/HYPERTENSIONAHA.111.175315.

44. Henegar J.R., Bigler S.A., Henegar L.K., Tyagi S.C., Hall J.E. Functional and structural changes in the kidney in the early stages of obesity. J. Am. Soc. Nephrol. 2001;12(6):1211–1217.

45. Knight S.F., Quigley J.E., Yuan J., Roy S.S., Elmarakby A., Imig J.D. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension. 2008;51(2):352–359.

46. Tsuboi N., Utsunomiya Y., Kanzaki G., Koike K., Ikegami M., Kawamura T., Hosoya T. Low glomerular density with glomerulomegaly in obesity-related glomerulopathy. Clin. J. Am. Soc. Nephrol. 2012;7(5):735–741. Doi: 10.2215/CJN.07270711.

47. Ribstein J., du C.G., Mimran A. Combined renal effects of overweight and hypertension. Hypertension. 1995;26(4):610–615.

48. Maalouf N.M., Sakhaee K., Parks J.H., Coe F.L., Adams-Huet B., Pak C.Y. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65(4):1422–1425.

49. Lemann J. Jr., Pleuss J.A., Worcester E.M., Hornick L., Schrab D., Hoffmann R.G. Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults. Kidney Int. 1996;49(1):200–208.

50. Siener R., Glatz S., Nicolay C., Hesse A. The role of overweight and obesity in calcium oxalate stone formation. Obes. Res. 2004;12(1):106–113.

51. Taylor E.N., Stampfer M.J., Curhan G.C. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68(3):1230–1235.

52. Klisic J., Hu M.C., Nief V., Reyes L., Fuster D., Moe O.W., Ambuhl P.M. Insulin activates Na(+)/H(+) exchanger 3: biphasic response and glucocorticoid dependence. Am. J. Physiol. Renal. Physiol. 200;283(3):F532–F539.

53. Chobanian M.C., Hammerman M.R. Insulin stimulates ammoniagenesis in canine renal proximal tubular segments. Am. J. Physiol. 1987;253(6 Pt 2):F1171–F1177.

54. Daudon M., Lacour B., Jungers P. Influence of body size on urinary stone composition in men and women. Urol. Res. 2006;34(3):193–199.

55. Sinha M.K., Collazo-Clavell M.L., Rule A., Milliner D.S., Nelson W., Sarr M.G., Kumar R., Lieske J.C. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 2007;72(1):100–107.

56. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer. 2004;4(8):579–591.

57. Dalamaga M., Diakopoulos K.N., Mantzoros C.S. The role of adiponectin in cancer: a review of current evidence. Endocr. Rev. 2012;33(4):547–594. Doi: 10.1210/er.2011–1015.

58. Lamas O., Marti A., Martinez J.A. Obesity and immunocompetence. Eur. J. Clin. Nutr. 2002;56(Suppl. 3):S42–S45.

59. Lim C., Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev. 2014;25(3):257–271. Doi: 10.1016/j.cytogfr.2014.04.005.

60. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. Doi: 10.1016/j.cell.2010.01.025.

61. Kovesdy C.P., Anderson J.E., Kalantar-Zadeh K. Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am. J. Kidney Dis. 2007;49:581–591. Doi: 10.1016/j.cell.2010.01.025.

62. Kalantar-Zadeh K., Kuwae N., Wu D.Y., Shantouf R.S., Fouque D., Anker S.D., Block G., Kopple J.D. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am. J. Clin. Nutr. 2006;83(2):202–210.

63. Beddhu S., Pappas L.M., Ramkumar N., Samore M. Effects of body size and body composition on survival in hemodialysis patients. J. Am. Soc. Nephrol. 2003;14(9):2366–2372.

64. Curtis J.P., Selter J.G., Wang Y., Rathore S.S., Jovin I.S., Jadbabaie F., Kosiborod M., Portnay E.L., Sokol S.I., Bader F., Krumholz H.M. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch. Intern. Med. 2005;165(1):55–61.

65. Wilson D.O., Rogers R.M., Wright E.C., Anthonisen N.R. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am. Rev. Respir. Dis. 1989;139(6):1435–1438.

66. Escalante A., Haas R.W., del Rincón I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch. Intern. Med. 2005;165(14):1624–1629.

67. Kalantar-Zadeh K., Kilpatrick R.D., Kuwae N., Wu D.Y. Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood. Purif. 2005;23(1):57–63.

68. Noori N., Kopple J.D., Kovesdy C.P., Feroze U., Sim J.J., Murali S.B., Luna A., Gomez M., Luna C., Bross R., Nissenson A.R., Kalantar-Zadeh K. Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2010;5(12):2258–2268. Doi: 10.2215/CJN.02080310.

69. Dekker F.W., de Mutsert R., van Dijk P.C., Zoccali C., Jager K.J. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int. 2008;74(8):994–997. Doi: 10.1038/ki.2008.328.

70. Snyder J.J., Foley R.N., Gilbertson D.T., Vonesh E.F., Collins A.J. Body size and outcomes on peritoneal dialysis in the United States. Kidney Int. 2003;64(5):1838–1844.

71. Lee P.S., Sampath K., Karumanchi S.A., Tamez H., Bhan I., Isakova T., Gutierrez O.M., Wolf M., Chang Y., Stossel T.P., Thadhani R. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J. Am. Soc. Nephrol. 2009;20(5):1140–1148. Doi: 10.1681/ASN.2008091008.

72. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., Woo M.A., Tillisch J.H. The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol. 2001;38(3):789–795.

73. Stenvinkel P., Marchlewska A., Pecoits-Filho R., Heimburger O., Zhang Z., Hoff C., Holmes C., Axelsson J., Arvidsson S., Schalling M., Barany P., Lindholm B., Nordfors L. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int. 2004;65(1):274–281.

74. Mohamed-Ali V., Goodrick S., Bulmer K., Holly J.M., Yudkin J.S., Coppack S.W. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am. J. Physiol. 1999;277(6 Pt. 1):E971–E975.

75. Rauchhaus M., Coats A.J., Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356(9233):930–933.

76. Jandacek R.J., Anderson N., Liu M., Zheng S., Yang Q., Tso P. Effects of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. Am. J. Physiol. Gastrointest. Liver. Physiol. 2005;288(2):G292–G299.

77. Kramer H.J., Saranathan A., Luke A., Durazo-Arvizu R.A., Guichan C., Hou S., Cooper R. Increasing body mass index and obesity in the incident ESRD population. J. Am. Soc. Nephrol. 2006;17(5):1453–1459.

78. Postorino M., Mancini E., D’Arrigo G., Marino C., Vilasi A., Tripepi G., Gallus S., Lugo A., Santoro A., Zoccali C. Body mass index trend in haemodialysis patients: the shift of nutritional disorders in two Italian regions. Nephrol. Dial. Transplant. 2016;31(10):1699–1705. Doi: 10.1093/ndt/gfw276.

79. 2008–2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. World Health Organization, 2009. URL: http://www.who.int

80. O’Donoghue D.J., Stevens P.E. A decade after the KDOQI CKD/guidelines: a perspective from the United Kingdom. Am. J. Kidney Dis. 2012;60(5):740–742. Doi: 10.1053/j.ajkd.2012.08.011.

81. Bolignano D., Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol. Dial. Transplant. 2013;28(Suppl. 4):iv82–iv98. Doi: 10.1093/ndt/gft302.

82. Chang Y., Ryu S., Choi Y., Zhang Y., Cho J., Kwon M.J., Hyun Y.Y., Lee K.B., Kim H., Jung H.S., Yun K.E., Ahn J., Rampal S., Zhao D., Suh B.S., Chung E.C., Shin H., Pastor-Barriuso R., Guallar E. Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study. Ann. Intern. Med. 2016;164(5):305–312. Doi: 10.7326/M15-1323.

83. Wing R.R., Bolin P., Brancati F.L., Bray G.A., Clark J.M., Coday M., Crow R.S., Curtis J.M., Egan C.M., Espeland M.A., Evans M., Foreyt J.P., Ghazarian S., Gregg E.W., Harrison B., Hazuda H.P., Hill J.O., Horton E.S., Hubbard V.S., Jakicic J.M., Jeffery R.W., Johnson K.C., Kahn S.E., Kitabchi A.E., Knowler W.C., Lewis C.E., Maschak-Carey B.J., Montez M.G., Murillo A., Nathan D.M., Patricio J., Peters A., Pi-Sunyer X., Pownall H., Reboussin D., Regensteiner J.G., Rickman A.D., Ryan D.H., Safford M., Wadden T.A., Wagenknecht L.E., West D.S., Williamson D.F., Yanovski S.Z. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 2013;369(2):145–154. Doi: 10.1056/NEJMoa1212914.

84. Mallamaci F., Ruggenenti P., Perna A., Leonardis D., Tripepi R., Tripepi G., Remuzzi G., Zoccali C. ACE inhibition is renoprotective among obese patients with proteinuria. J. Am. Soc. Nephrol. 2011;22(6):1122–1128. Doi: 10.1681/ASN.2010090969.

85. Friedman A.N., Wolfe B. Is Bariatric Surgery an Effective Treatment for Type II Diabetic Kidney Disease? Clin. J. Am. Soc. Nephrol. 2016;11(3):528–535. Doi: 10.2215/CJN.07670715.

86. Chang A.R., Chen Y., Still C., Wood G.C., Kirchner H.L., Lewis M., Kramer H., Hartle J.E., Carey D., Appel L.J., Grams M.E. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int. 2016;90(1):164–171. Doi: 10.1016/j.kint.2016.02.039.

87. Jamal M.H., Corcelles R., Daigle C.R., Rogula T., Kroh M., Schauer P.R., Brethauer S.A. Safety and effectiveness of bariatric surgery in dialysis patients and kidney transplantation candidates. Surg. Obes. Relat. Dis. 2015;11(2):419–423. Doi: 10.1016/j.soard.2014.09.022.

88. Ahmadi S.F., Zahmatkesh G., Ahmadi E., Streja E., Rhee C.M., Gillen D.L., De Nicola L., Minutolo R., Ricardo A.C., Kovesdy C.P., Kalantar-Zadeh K. Association of Body Mass Index with Clinical Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Cardiorenal. Med. 2015;6(1):37–49. Doi: 10.1159/000437277.